Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen has received a positive opinion from the Committee for Medicinal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE